Cargando…
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783108/ https://www.ncbi.nlm.nih.gov/pubmed/36560590 http://dx.doi.org/10.3390/vaccines10122180 |
_version_ | 1784857499615100928 |
---|---|
author | Pratama, Nando Reza Wafa, Ifan Ali Budi, David Setyo Sutanto, Henry Asmarawati, Tri Pudy Barlian Effendi, Gema Wungu, Citrawati Dyah Kencono |
author_facet | Pratama, Nando Reza Wafa, Ifan Ali Budi, David Setyo Sutanto, Henry Asmarawati, Tri Pudy Barlian Effendi, Gema Wungu, Citrawati Dyah Kencono |
author_sort | Pratama, Nando Reza |
collection | PubMed |
description | Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time. |
format | Online Article Text |
id | pubmed-9783108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97831082022-12-24 Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression Pratama, Nando Reza Wafa, Ifan Ali Budi, David Setyo Sutanto, Henry Asmarawati, Tri Pudy Barlian Effendi, Gema Wungu, Citrawati Dyah Kencono Vaccines (Basel) Review Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time. MDPI 2022-12-19 /pmc/articles/PMC9783108/ /pubmed/36560590 http://dx.doi.org/10.3390/vaccines10122180 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pratama, Nando Reza Wafa, Ifan Ali Budi, David Setyo Sutanto, Henry Asmarawati, Tri Pudy Barlian Effendi, Gema Wungu, Citrawati Dyah Kencono Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title | Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title_full | Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title_fullStr | Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title_full_unstemmed | Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title_short | Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression |
title_sort | effectiveness of covid-19 vaccines against sars-cov-2 omicron variant (b.1.1.529): a systematic review with meta-analysis and meta-regression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783108/ https://www.ncbi.nlm.nih.gov/pubmed/36560590 http://dx.doi.org/10.3390/vaccines10122180 |
work_keys_str_mv | AT pratamanandoreza effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT wafaifanali effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT budidavidsetyo effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT sutantohenry effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT asmarawatitripudy effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT barlianeffendigema effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression AT wungucitrawatidyahkencono effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression |